nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Abstracts selected for a poster presentation
|
|
|
2002 |
38 |
S6 |
p. 87-95 9 p. |
artikel |
2 |
Adjuvant hormone therapy following primary therapy for endometrial cancer
|
Loibl, S |
|
2002 |
38 |
S6 |
p. 41-43 3 p. |
artikel |
3 |
Anastrozole versus progestins/tamoxifen
|
Beat, Thuerlimann |
|
2002 |
38 |
S6 |
p. 49-51 3 p. |
artikel |
4 |
An update on non-gynaecological effects of SERM's and aromatase inhibitors
|
Netelenbos, C |
|
2002 |
38 |
S6 |
p. 63-64 2 p. |
artikel |
5 |
An update on non-uterine gynaecological effects on raloxifene
|
Goldstein, S.R |
|
2002 |
38 |
S6 |
p. 65-66 2 p. |
artikel |
6 |
Aromatase inhibitors and inactivators for breast cancer treatment
|
Lonning, P.E |
|
2002 |
38 |
S6 |
p. 47-48 2 p. |
artikel |
7 |
Arzoxifene in breast cancer
|
Chan, S |
|
2002 |
38 |
S6 |
p. 55-56 2 p. |
artikel |
8 |
Endocrine prevention of breast: any role for tibolone?
|
Kloosterboer, H.J |
|
2002 |
38 |
S6 |
p. 24-25 2 p. |
artikel |
9 |
Endocrine treatment and prevention of breast and gynaecological cancers
|
Neven, P. |
|
2002 |
38 |
S6 |
p. 1-11 11 p. |
artikel |
10 |
Endometrial evaluation is a very important tool in the management of breast cancer patients
|
Berlière, M |
|
2002 |
38 |
S6 |
p. 67-68 2 p. |
artikel |
11 |
Expression of oestrogen receptor α and β in uterine endometrial and ovarian cancers
|
Sakaguchi, H |
|
2002 |
38 |
S6 |
p. 74-75 2 p. |
artikel |
12 |
Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women
|
Vergote, I |
|
2002 |
38 |
S6 |
p. 57-58 2 p. |
artikel |
13 |
How do endogenous oestrogens affect breast cancer?
|
Fentiman, I.S |
|
2002 |
38 |
S6 |
p. 59-60 2 p. |
artikel |
14 |
IL-1α gene expression in human endometrial cancer is independent of ovarian steroid receptor expression
|
Singer, C.F |
|
2002 |
38 |
S6 |
p. 76-77 2 p. |
artikel |
15 |
Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer
|
Piccart, M.J |
|
2002 |
38 |
S6 |
p. 52-54 3 p. |
artikel |
16 |
LHRH-agonist versus chemotherapy in premenopausal breast cancer?
|
Klijn, J.G.M |
|
2002 |
38 |
S6 |
p. 45-46 2 p. |
artikel |
17 |
Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer
|
Hanekamp, E.E |
|
2002 |
38 |
S6 |
p. 71-72 2 p. |
artikel |
18 |
New SERMs in development
|
Neven, P |
|
2002 |
38 |
S6 |
p. 26-27 2 p. |
artikel |
19 |
No rules without exception: a long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer
|
Paskeviciute, L |
|
2002 |
38 |
S6 |
p. 73- 1 p. |
artikel |
20 |
Oestrogen receptor determination in breast and gynaecological tissue. What is the best approach to reproducible measurement?
|
Leake, R |
|
2002 |
38 |
S6 |
p. 33-34 2 p. |
artikel |
21 |
Pathways of carcinogenesis and prevention in the human breast
|
Russo, J |
|
2002 |
38 |
S6 |
p. 31-32 2 p. |
artikel |
22 |
Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
|
Rebbeck, T.R. |
|
2002 |
38 |
S6 |
p. 15-17 3 p. |
artikel |
23 |
Rationale for a study adding tamoxifen to HRT
|
Rotmensz, N |
|
2002 |
38 |
S6 |
p. 22-23 2 p. |
artikel |
24 |
Role of LHRH agonists in premenopausal women with oestrogen receptor-positive breast cancer: the ZEBRA experience
|
Jonat, W |
|
2002 |
38 |
S6 |
p. 39-40 2 p. |
artikel |
25 |
Selective oestrogen receptor downregulator
|
Howell, Anthony |
|
2002 |
38 |
S6 |
p. 61-62 2 p. |
artikel |
26 |
SERMs: how do they work?
|
Draper, M.W |
|
2002 |
38 |
S6 |
p. 35- 1 p. |
artikel |
27 |
Short Abstracts
|
|
|
2002 |
38 |
S6 |
p. 81-86 6 p. |
artikel |
28 |
Short Abstracts
|
|
|
2002 |
38 |
S6 |
p. IFC- 1 p. |
artikel |
29 |
Tamoxifen for primary breast cancer prevention in BRCA heterozygotes
|
Robson, M |
|
2002 |
38 |
S6 |
p. 18-19 2 p. |
artikel |
30 |
Tamoxifen versus raloxifene in the prevention of breast cancer
|
Wickerham, D.L |
|
2002 |
38 |
S6 |
p. 20-21 2 p. |
artikel |
31 |
Tamoxifen versus toremifene in the adjuvant treatment of breast cancer
|
Holli, K |
|
2002 |
38 |
S6 |
p. 37-38 2 p. |
artikel |
32 |
The effect of continuous combined 17β-oestradiol and dihydrodydrogesterone on apoptotic cell death and proliferation of human breast cancer cells in vitro
|
Franke, H.R |
|
2002 |
38 |
S6 |
p. 69-70 2 p. |
artikel |
33 |
The influence of hormone replacement therapy on the ultrasound features of the endometrium: a prospective study
|
Van den Bosch, T |
|
2002 |
38 |
S6 |
p. 78-79 2 p. |
artikel |
34 |
The origin of postmenopausal oestrogens
|
Neven, P |
|
2002 |
38 |
S6 |
p. 29-30 2 p. |
artikel |
35 |
Written report of presented lectures: endocrine treatment and prevention of breast and gynaecological cancers
|
Howell, A |
|
2002 |
38 |
S6 |
p. 13-14 2 p. |
artikel |